RT Journal Article
T1 Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease.
A1 Villarejo-Galende, Alberto
A1 García-Arcelay, Elena
A1 Piñol-Ripoll, Gerard
A1 Del Olmo-Rodríguez, Antonio
A1 Viñuela, Félix
A1 Boada, Mercè
A1 Franco-Macías, Emilio
A1 Ibañez de la Peña, Almudena
A1 Riverol, Mario
A1 Puig-Pijoan, Albert
A1 Abizanda-Soler, Pedro
A1 Arroyo, Rafael
A1 Baquero-Toledo, Miquel
A1 Feria-Vilar, Inmaculada
A1 Balasa, Mircea
A1 Berbel, Ángel
A1 Rodríguez-Rodríguez, Eloy
A1 Vieira-Campos, Alba
A1 García-Ribas, Guillermo
A1 Rodrigo-Herrero, Silvia
A1 Terrancle, Ángeles
A1 Prefasi, Daniel
A1 Lleó, Alberto
A1 Maurino, Jorge
K1 Alzheimer’s disease
K1 amyloid
K1 biomarkers
K1 cerebrospinal fluid
K1 magnetic resonance imaging
K1 tau proteins
K1 white matter hyperintensities
K1 white matter lesions
AB There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/20512
UL http://hdl.handle.net/10668/20512
LA en
DS RISalud
RD Apr 11, 2025